BioSpace News Archive

AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that the Biomedical Advanced Research and Development Authority (BA

Endpoint Health launched today on a mission to bring life-saving targeted therapies to patients with critical illnesses including sepsis and acute respiratory distress syndrome (ARDS) — life-threatening conditions often caused by serious infections, including COVID-19.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that the first patient was randomized in the INFINITY clinical trial to evaluate ADVM-022 for the treatment of diabetic macular edema (DME).

ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today reported financial results for the second quarter ended 30 June 2020 and provided an update on its clinical activities. Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, said : “As COVID-19 restrictions gradually lift in Singapore we expe

Syneos Health ® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that it has signed a new three-year agreement with Pfizer Inc. (NYSE: PFE) to deliver global product development solutions to support Pfizer’s portfolio. Under the terms of the agreement, Pfizer has the right to extend the term for up to an additional two years. Financial details of the agreement were not disclosed. This agre

Initiation of the COViNOX Study Follows the Conclusion of the FDA Emergency Access Program Through Which 180 Patients with COVID-19 Were Treated in the United States

ACell, Inc., a leading regenerative medicine company focused on the development, manufacture and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects, announced today that it has launched the roadshow for the initial

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced that effective as of market open on July 14, 2020 , its common stock has been approved for uplisting to the Nasdaq Global Select Market ® and will continue trading under its

BioSerenity, a high growth company specializing in remote diagnostic solutions for Neurology, Sleep Medicine and Cardiology announces an article published in Epilepsy & Behavior describing deployment of innovative virtual clinics to provide improved access to care for people suffering from epilepsy. Healthcare access rem

Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its second-quarter 2020 financial results will be released on Wednesday, Aug. 5, 2020. Following the announcement, Horizon’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com . Please connect to the Company’s website